ETF Holdings Breakdown of LEGN

Stock Name	Legend Biotech Corp
Ticker	LEGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US52490G1022
LEI	254900EIUFZTW136H859

LEGN institutional holdings

The adjusted close for LEGN on 2025-11-11 was 32.03

The following institutional investment holdings of LEGN have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BKM4GZ66 (iShares Core MSCI EM IMI UCITS ETF USD (Acc))	209,479	USD 6,709,612 1.4%	32.03
2025-11-11	IE00BD45KH83 (iShares Core MSCI EM IMI UCITS ETF USD (Dist) GBP)	209,479	USD 6,709,612	32.03
2025-11-11	IE00B6R52259 (iShares MSCI ACWI UCITS ETF)	18,127	USD 580,608	32.03
2025-11-11	IE00BHZPJ239 (iShares MSCI EM ESG Enhanced UCITS ETF USD Acc)	14,573	USD 466,773	32.03
2025-11-11	IE00BHZPJ122 (iShares MSCI EM ESG Enhanced UCITS ETF USD Inc GBP)	14,573	USD 466,773 1.4%	32.03
2025-11-11	IE00B0M63177 (iShares MSCI EM UCITS ETF USD (Dist) USD)	40,856	USD 1,308,618 1.4%	32.03
2025-11-11	IE00BFNM3N12 (iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist))	45,905	USD 1,470,337 1.4%	32.03
2025-11-11	IE00BFNM3P36 (iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc) GBP)	45,905	USD 1,470,337	32.03
2025-11-11	IE00B4L5YC18 (iShares MSCI EM UCITS ETF USD (Acc))	43,779	USD 1,402,241	32.03
2025-11-11	IE00B5L8K969 (iShares VII PLC - iShares MSCI EM Asia ETF USD Acc USD)	38,706	USD 1,239,753 1.4%	32.03
2025-11-11	IE00BJ5JPG56 (iShares MSCI China UCITS ETF USD Acc)	118,977	USD 3,810,833	32.03
2025-11-11	IE00BL977C92 (iShares MSCI China UCITS ETF)	118,977	USD 3,810,833	32.03
2025-11-11	IE00B0M63730 (iShares MSCI AC Far East ex-Japan UCITS ETF USD (Dist) USD)	10,399	USD 333,080	32.03
2025-11-11	IE00BKPX3K41 (iShares MSCI AC Far East ex-Japan UCITS ETF USD (Acc))	10,399 -1.3%	USD 333,080 0.1%	32.03
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	54,510	USD 1,745,955	32.03
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	54,510	USD 1,745,955	32.03
2025-11-11	IE00B8KGV557 (iShares Edge MSCI EM Minimum Volatility UCITS ETF)	23,387	USD 749,086 1.4%	32.03
2025-11-10	IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc))	18,127	USD 572,632 -0.7%	31.59
Total =	1,090,668	USD 34,926,118

News associated with LEGN

Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $74.22: Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price […] - 2025-09-19 02:43:01
Legend Biotech Becomes Oversold (LEGN): Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-09-10 14:53:11
JPMorgan Chase & Co. Increases Legend Biotech (NASDAQ:LEGN) Price Target to $78.00: Legend Biotech (NASDAQ:LEGN – Get Free Report) had its price target raised by research analysts at JPMorgan Chase & Co. from $77.00 to $78.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of […] - 2025-08-27 02:30:45
Legend Biotech Breaks Below 200-Day Moving Average - Notable for LEGN: In trading on Monday, shares of Legend Biotech Corp (Symbol: LEGN) crossed below their 200 day moving average of $36.28, changing hands as low as $35.23 per share. Legend Biotech Corp shares are currently trading off about 2.5% on the day. The chart below shows the one year pe - 2025-08-11 12:46:01
Legend Biotech (NASDAQ:LEGN) Rating Increased to Strong-Buy at Cantor Fitzgerald: Legend Biotech (NASDAQ:LEGN – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports. Other equities research analysts also recently issued research reports about the company. Johnson Rice reissued a “buy” rating on shares of Legend Biotech in a research report on […] - 2025-08-06 03:12:50
GAMMA Investing LLC Boosts Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN): GAMMA Investing LLC increased its holdings in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 145.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,291 shares of the company’s stock after purchasing an additional 765 […] - 2025-07-11 04:12:51
Legend Biotech (NASDAQ:LEGN) Receives Buy Rating from HC Wainwright: Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $75.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 90.07% from the company’s previous close. A number of other […] - 2025-07-10 04:01:26
Rhumbline Advisers Purchases 391 Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN): Rhumbline Advisers lifted its position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,029 shares of the company’s stock after acquiring an additional 391 shares during the quarter. Rhumbline Advisers’ holdings […] - 2025-06-20 04:25:11
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 36,181 Shares of Legend Biotech Co. (NASDAQ:LEGN): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 36.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,438 shares of the company’s stock after […] - 2025-06-04 05:02:51
Nuveen Asset Management LLC Acquires 5,700 Shares of Legend Biotech Co. (NASDAQ:LEGN): Nuveen Asset Management LLC grew its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 5.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 110,586 shares of the company’s stock after purchasing an additional 5,700 shares during the period. Nuveen Asset Management LLC’s […] - 2025-06-02 05:04:55
Legend Biotech Co. (NASDAQ:LEGN) Shares Acquired by Squarepoint Ops LLC: Squarepoint Ops LLC grew its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 44.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,900 shares of the company’s stock after acquiring an additional 39,197 shares during the quarter. Squarepoint Ops […] - 2025-05-27 05:13:00
Millennium Management LLC Has $8.31 Million Holdings in Legend Biotech Co. (NASDAQ:LEGN): Millennium Management LLC lessened its stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 255,468 shares of the company’s stock after selling 314,908 shares during the quarter. Millennium Management LLC’s […] - 2025-05-26 04:42:54
Deutsche Bank AG Acquires 14,198 Shares of Legend Biotech Co. (NASDAQ:LEGN): Deutsche Bank AG lifted its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 11.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 135,067 shares of the company’s stock after acquiring an additional 14,198 shares during the period. Deutsche Bank […] - 2025-05-20 05:12:55
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month Low After Analyst Downgrade: Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) hit a new 52-week low during mid-day trading on Thursday after Truist Financial lowered their price target on the stock from $88.00 to $71.00. Truist Financial currently has a buy rating on the stock. Legend Biotech traded as low as $27.54 and last traded at […] - 2025-05-16 03:02:47
Legend Biotech Co. (NASDAQ:LEGN) Stake Boosted by Stifel Financial Corp: Stifel Financial Corp increased its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 70.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,365 shares of the company’s stock after acquiring an additional 12,955 shares […] - 2025-05-09 05:58:54
Zurcher Kantonalbank Zurich Cantonalbank Trims Position in Legend Biotech Co. (NASDAQ:LEGN): Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 18.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 40,913 shares of the company’s stock after selling 9,355 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Legend […] - 2025-03-19 05:40:51
Morgan Stanley Issues Pessimistic Forecast for Legend Biotech (NASDAQ:LEGN) Stock Price: Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price dropped by analysts at Morgan Stanley from $82.00 to $80.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 111.19% from the company’s current […] - 2025-03-19 04:28:56
Daiwa Securities Group Inc. Raises Stock Position in Legend Biotech Co. (NASDAQ:LEGN): Daiwa Securities Group Inc. lifted its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 165.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,516 shares of the company’s stock after acquiring an additional 5,309 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Legend Biotech were worth $278,000 as […] - 2025-03-17 06:06:55
Company News for Mar 12, 2025: Companies in The News Are: FRG, ORCL, LEGN, PAY - 2025-03-12 11:20:00
Legend Biotech Co. (NASDAQ:LEGN) Receives $79.50 Average PT from Brokerages: Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have been given a consensus rating of “Buy” by the twelve research firms that are covering the stock, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock […] - 2025-03-03 04:50:55
Legend Biotech Co. (NASDAQ:LEGN) Shares Sold by Sumitomo Mitsui Trust Group Inc.: Sumitomo Mitsui Trust Group Inc. lowered its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 173,766 shares of the company’s stock after selling 3,461 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-02-14 07:35:09
Contrasting Legend Biotech (NASDAQ:LEGN) and COMPASS Pathways (NASDAQ:CMPS): COMPASS Pathways (NASDAQ:CMPS – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Earnings & Valuation This table compares COMPASS Pathways […] - 2025-02-06 04:06:58

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.